Overview ALC-919 For The Treatment Of Common Warts Status: Completed Trial end date: 2015-10-01 Target enrollment: Participant gender: Summary This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment. Phase: Phase 2 Details Lead Sponsor: ALC Therapeutics, LLCVeloce BioPharma LLCTreatments: Pharmaceutical Solutions